uniQure NV (MEX:QUREN) Construction In Progress: MXN0.0 Mil (As of Mar. 2026)


MEX:QUREN uniQure NV MEX:QUREN
29 GF Score
Price MXN795.45
GF Value MXN99.43
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV Construction In Progress?

uniQure NV MEX:QUREN 29 Construction In Progress is MXN0.0 Mil as of Mar. 2026. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 5 warning signs investors should review.

uniQure NV's annual construction in progress declined from Dec. 2023 (MXN96.2 Mil) to Dec. 2024 (MXN0.0 Mil) but then stayed the same from Dec. 2024 (MXN0.0 Mil) to Dec. 2025 (MXN0.0 Mil).

uniQure NV Construction In Progress Historical Data

* Premium members only.

The historical data trend for uniQure NV's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV Construction In Progress Chart

uniQure NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103.99 105.45 96.21 0.00 0.00

uniQure NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:QUREN
29GF Score
uniQure NV MEX:QUREN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

uniQure NV Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN0.0 Mil mean?
uniQure NV (MEX:QUREN) has a Construction In Progress of MXN0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on uniQure NV and its competitors.
Is uniQure NV's Construction In Progress too high?
uniQure NV's current Construction In Progress is MXN0.0 Mil. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Construction In Progress compare to NVAX and HRMY?
uniQure NV's Construction In Progress of MXN0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on uniQure NV and its competitors. uniQure NV's current Construction In Progress is MXN0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current Construction In Progress is MXN0.0 Mil. uniQure NV's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current Construction In Progress is MXN0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (MEX:QUREN) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for MEX:QUREN:

  • Construction In Progress: MXN0.0 Mil
  • GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Other Exchanges QURE:USA0EE0:UKUQ1:Germany
Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
29GF Score

Get the complete analysis for MEX:QUREN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN795.45
Price
MXN99.43
GF Value